| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050840001 |
| P356 | DOI | 10.1186/1471-244X-13-273 |
| P932 | PMC publication ID | 4015603 |
| P698 | PubMed publication ID | 24143878 |
| P2093 | author name string | Alan R Light | |
| Ronald W Hughen | |||
| Andrea T White | |||
| Eli Iacob | |||
| Kathleen C Light | |||
| Timothy A Vanhaitsma | |||
| Scott C Tadler | |||
| Howard R Weeks | |||
| Lowry Bushnell | |||
| P2860 | cites work | A rating scale for depression | Q24564540 |
| Oxytocin receptor gene (OXTR) is related to psychological resources | Q24635951 | ||
| Development of a Rating Scale for Primary Depressive Illness | Q29616244 | ||
| A meta-analysis of cytokines in major depression | Q29617325 | ||
| Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression | Q29617326 | ||
| A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 | ||
| Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects | Q33503890 | ||
| Transcriptional expression of serotonergic regulators in laser-captured microdissected dorsal raphe neurons of subjects with major depressive disorder: sex-specific differences | Q33514090 | ||
| Oxytocin and Major Depressive Disorder: Experimental and Clinical Evidence for Links to Aetiology and Possible Treatment | Q33664227 | ||
| Gene expression studies in major depression. | Q33762208 | ||
| Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression--evolution of antidepressants and the role of the "neuro-immune" system | Q33992026 | ||
| The role of purinergic signaling in depressive disorders | Q34034901 | ||
| Gender differences in depression. Critical review | Q34096002 | ||
| Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin | Q34118114 | ||
| Oxytocin: a therapeutic target for mental disorders | Q34301630 | ||
| Oxytocin receptor gene polymorphism (rs2254298) interacts with familial risk for psychopathology to predict symptoms of depression and anxiety in adolescent girls. | Q34384624 | ||
| Immune suppression and immune activation in depression | Q34511208 | ||
| P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide | Q34623752 | ||
| Effects of antidepressants on the production of cytokines | Q35017013 | ||
| Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome | Q35219064 | ||
| The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis | Q35356649 | ||
| Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression | Q35613219 | ||
| Emerging adenosine receptor agonists: an update | Q35682324 | ||
| Current understanding of the bi-directional relationship of major depression with inflammation | Q36061675 | ||
| Evidence of dysregulated peripheral oxytocin release among depressed women. | Q36096630 | ||
| Cytokines in schizophrenia and the effects of antipsychotic drugs | Q36437626 | ||
| Foetal origins of depression? A systematic review and meta-analysis of low birth weight and later depression | Q36463794 | ||
| A detailed examination of cytokine abnormalities in Major Depressive Disorder | Q36496289 | ||
| Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. | Q36539999 | ||
| Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder | Q36610063 | ||
| Bipolar depression: diagnostic and treatment considerations | Q36634433 | ||
| Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder | Q36651524 | ||
| Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. | Q37103988 | ||
| Glucocorticoid antagonists in neuropsychiatric [corrected] disorders | Q37109672 | ||
| Cognitive trio: relationship with major depression and clinical predictors in Han Chinese women | Q37253631 | ||
| Acid-sensing ion channel-1a in the amygdala, a novel therapeutic target in depression-related behavior | Q37262543 | ||
| Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects | Q37376370 | ||
| Oxytocin, vasopressin, and human social behavior | Q37511061 | ||
| The P2X7 purinergic receptor: from physiology to neurological disorders. | Q37610687 | ||
| Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression | Q37752679 | ||
| Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides | Q38033226 | ||
| The correlation of plasma Aβ42 levels, depressive symptoms, and cognitive function in the Korean elderly | Q38473582 | ||
| Metabolism of amyloid-β protein may be affected in depression | Q39677668 | ||
| Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: involvement of nitric oxide. | Q43594745 | ||
| Stimulation of P2Y1 receptors causes anxiolytic-like effects in the rat elevated plus-maze: implications for the involvement of P2Y1 receptor-mediated nitric oxide production | Q44357511 | ||
| Population-specific functional variant of the TPH2 gene 2755C>A polymorphism contributes risk association to major depression and anxiety in Chinese peripartum women. | Q45934609 | ||
| Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder | Q46355585 | ||
| Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. | Q46518412 | ||
| Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. | Q46627691 | ||
| A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. | Q46662600 | ||
| A possible participation of transient receptor potential vanilloid type 1 channels in the antidepressant effect of fluoxetine | Q47837146 | ||
| Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. | Q48296018 | ||
| P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder | Q48478326 | ||
| Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity. | Q48499472 | ||
| Plasma levels of arginine vasopressin elevated in patients with major depression | Q48609918 | ||
| Differential expression of genes encoding neuronal ion-channel subunits in major depression, bipolar disorder and schizophrenia: implications for pathophysiology | Q48831250 | ||
| Intranasal oxytocin as an adjunct to escitalopram in major depression | Q48849702 | ||
| P2RX7: A bipolar and unipolar disorder candidate susceptibility gene? | Q50605593 | ||
| Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. | Q51616268 | ||
| Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. | Q51996803 | ||
| The association between oxytocin receptor gene (OXTR) polymorphisms and affective temperaments, as measured by TEMPS-A. | Q53173988 | ||
| Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine | Q57231903 | ||
| The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression | Q57616579 | ||
| Cytokine production and treatment response in major depressive disorder | Q73505932 | ||
| Depression, antidepressants, and plasma amyloid beta (Beta) peptides in those elderly who do not have cardiovascular disease | Q80419781 | ||
| Treatment-resistant depression | Q84268979 | ||
| P304 | page(s) | 273 | |
| P577 | publication date | 2013-10-21 | |
| P1433 | published in | BMC Psychiatry | Q15750257 |
| P1476 | title | Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls | |
| P478 | volume | 13 |
| Q38823641 | Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response |
| Q48036751 | Effects of intranasal administration of the peptide antagonist of type I vaniloid receptor (TRPV1) in the rodent central nervous system. |
| Q36957582 | GLUCOCORTICOID RECEPTOR-RELATED GENES: GENOTYPE AND BRAIN GENE EXPRESSION RELATIONSHIPS TO SUICIDE AND MAJOR DEPRESSIVE DISORDER |
| Q36386524 | Gene Expression Factor Analysis to Differentiate Pathways Linked to Fibromyalgia, Chronic Fatigue Syndrome, and Depression in a Diverse Patient Sample |
| Q33562637 | Leukocyte Gene Expression in Patients with Medication Refractory Depression before and after Treatment with ECT or Isoflurane Anesthesia: A Pilot Study |
| Q34674792 | Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics |
| Q37394229 | Replication of genome-wide association study (GWAS) susceptibility loci in a Latino bipolar disorder cohort. |
| Q55044779 | Transient Receptor Potential Channels as Blood Biomarkers for Pain Characteristics in Patients with Chronic Pain. |
Search more.